CHRIS AMOS to Genes, BRCA2
This is a "connection" page, showing publications CHRIS AMOS has written about Genes, BRCA2.
Connection Strength
1.009
-
Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006 Jan 20; 24(3):354-60.
Score: 0.244
-
Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. J Invest Dermatol. 2015 Feb; 135(2):542-550.
Score: 0.111
-
Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast. 2014 Dec; 23(6):770-4.
Score: 0.111
-
Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol. 2014 Apr 20; 32(12):1249-55.
Score: 0.108
-
Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011 Mar-Apr; 17(2):210-2.
Score: 0.087
-
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8.
Score: 0.073
-
BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 2007 Oct 10; 25(29):4635-41.
Score: 0.069
-
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007 Oct 02; 147(7):441-50.
Score: 0.069
-
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006 Feb 20; 24(6):863-71.
Score: 0.061
-
Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst. 2003 Jan 01; 95(1):74-5; author reply 77-8.
Score: 0.049
-
Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2013 Jun; 139(2):571-9.
Score: 0.025